Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial -

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Information type: Randomised controlled trials
Source: The Lancet
Specialities: Diabetes
Summary
At week 26, RCT (n=711) found that semaglutide was non-inferior to liraglutide and superior to placebo in decreasing HbA1c, (-1.2%, -1.1% and -0.2%, respectively) and superior in decreasing BMI vs liraglutide and placebo (difference −1.5 and−4.0 kg; p<0.0001).
UKMi comment
The authors of a related commentary note that since the results with both GLP-1 receptor agonists were similar, this would suggest a clinical scenario in which patients and clinicians could have a choice; to take a daily pill or a daily injection.
Related links: Comment